发布于: | 雪球 | 转发:0 | 回复:3 | 喜欢:0 |
$再鼎医药(09688)$ 放弃margetuximab和Odronextamab的开发,是不是2025年实现盈利就变得更加确定了?margetuximab已经被NMPA批准,不知道是否有支付里程碑付款,而FDA对Odronextamab治疗FL和DLBCL的优先审查,已将2024年3月31日定为PDUFA行动日期。如果FDA批准其上市,再鼎是需要支付一笔不菲的里...
Collaboration revenue for the fourth quarter and full year in 2023 was $32 million and $36 million, respectively, compared to $1 million and $10 million for the same periods in 2022. The increase is mainly related to the clinical development milestone argenx achieved with AbbVie following the dosing of the first patient in the Phase 2 trial for ABBV-151. Collaboration revenue for full year in 2023 also includes $1 million in royalty revenue from VYVGART sales in China.